Sign In
Buy MLYS
$25.61
+0.240 (+0.95%)
At Close: Jun 23, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07:00pm, Wednesday, 11'th Feb 2026
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and relate
Mineralys Therapeutics Sees Unusually Large Options Volume (NASDAQ:MLYS)
01:16am, Saturday, 07'th Feb 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) was the recipient of some unusual options trading on Friday. Investors purchased 92,406 put options on the company. This represents an inc
Dow Eyes Best Day in 10 Months as Tech Rebound Lifts Sentiment
12:36pm, Friday, 06'th Feb 2026
The Dow is eyeing its best day in 10 months, as a bounce back in tech and software stocks lift Wall street
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $252,469.75 in Stock
06:12am, Sunday, 18'th Jan 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 7,709 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an averag
Adam Scott Levy Sells 10,758 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
05:48am, Thursday, 15'th Jan 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CFO Adam Scott Levy sold 10,758 shares of the company's stock in a transaction that occurred on Monday, January 12th. The shares were sold
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
05:48am, Thursday, 15'th Jan 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 6,348 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average pr
Jon Congleton Sells 16,236 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
05:00am, Thursday, 15'th Jan 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CEO Jon Congleton sold 16,236 shares of Mineralys Therapeutics stock in a transaction on Monday, January 12th. The shares were sold at an
SG Americas Securities LLC Sells 23,950 Shares of Mineralys Therapeutics, Inc. $MLYS
05:43am, Monday, 12'th Jan 2026
SG Americas Securities LLC lowered its position in Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 19.3% in the third quarter, according to the company in its most recent disclosure with the Securities
David Malcom Rodman Sells 70,037 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
04:48am, Thursday, 08'th Jan 2026
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 70,037 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The stock wa
RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and relate
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Recommendation of “Moderate Buy” by Brokerages
01:26am, Wednesday, 31'st Dec 2025
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat reports. One investmen
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026
08:03am, Sunday, 28'th Dec 2025
Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million. MLYS's lorundrostat demonstrated significant efficacy
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
03:35am, Friday, 26'th Dec 2025
Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
11:56am, Wednesday, 24'th Dec 2025
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
12:07pm, Tuesday, 23'rd Dec 2025
New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous period.
